Comparative Pharmacology
Head-to-head clinical analysis: OLOPATADINE HYDROCHLORIDE versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OLOPATADINE HYDROCHLORIDE versus PROMETHAZINE DM.
OLOPATADINE HYDROCHLORIDE vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olopatadine hydrochloride is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits histamine release from mast cells and prevents histamine-induced effects such as increased vascular permeability and pruritus.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
One drop of 0.1% or 0.2% ophthalmic solution in each affected eye twice daily (every 6-8 hours) for 0.1%; once daily for 0.2%.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
Terminal elimination half-life of 8–12 hours in healthy adults; prolonged in hepatic impairment (up to 18 hours)
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Primarily renal excretion (60-70% unchanged), with minor biliary/fecal elimination (~30% as metabolites)
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category A/B
Category A/B
Antihistamine / Mast Cell Stabilizer
Antihistamine / Antiemetic